Reducing gut microbiome-driven adipose tissue inflammation alleviates metabolic syndrome. 2023

N K Newman, and Y Zhang, and J Padiadpu, and C L Miranda, and A A Magana, and C P Wong, and K A Hioki, and J W Pederson, and Z Li, and M Gurung, and A M Bruce, and K Brown, and G Bobe, and T J Sharpton, and N Shulzhenko, and C S Maier, and J F Stevens, and A F Gombart, and A Morgun
Department of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, Corvallis, OR, USA.

The gut microbiota contributes to macrophage-mediated inflammation in adipose tissue with consumption of an obesogenic diet, thus driving the development of metabolic syndrome. There is a need to identify and develop interventions that abrogate this condition. The hops-derived prenylated flavonoid xanthohumol (XN) and its semi-synthetic derivative tetrahydroxanthohumol (TXN) attenuate high-fat diet-induced obesity, hepatosteatosis, and metabolic syndrome in C57Bl/6J mice. This coincides with a decrease in pro-inflammatory gene expression in the gut and adipose tissue, together with alterations in the gut microbiota and bile acid composition. In this study, we integrated and interrogated multi-omics data from different organs with fecal 16S rRNA sequences and systemic metabolic phenotypic data using a Transkingdom Network Analysis. By incorporating cell type information from single-cell RNA-seq data, we discovered TXN attenuates macrophage inflammatory processes in adipose tissue. TXN treatment also reduced levels of inflammation-inducing microbes, such as Oscillibacter valericigenes, that lead to adverse metabolic phenotypes. Furthermore, in vitro validation in macrophage cell lines and in vivo mouse supplementation showed addition of O. valericigenes supernatant induced the expression of metabolic macrophage signature genes that are downregulated by TXN in vivo. Our findings establish an important mechanism by which TXN mitigates adverse phenotypic outcomes of diet-induced obesity and metabolic syndrome. TXN primarily reduces the abundance of pro-inflammatory gut microbes that can otherwise promote macrophage-associated inflammation in white adipose tissue. Video Abstract.

UI MeSH Term Description Entries
D007249 Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function. Innate Inflammatory Response,Inflammations,Inflammatory Response, Innate,Innate Inflammatory Responses
D009765 Obesity A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
D000069196 Gastrointestinal Microbiome All of the microbial organisms that naturally exist within the GASTROINTESTINAL TRACT. Enteric Bacteria,Gastric Microbiome,Gastrointestinal Flora,Gastrointestinal Microbial Community,Gastrointestinal Microbiota,Gastrointestinal Microflora,Gut Flora,Gut Microbiome,Gut Microbiota,Gut Microflora,Intestinal Flora,Intestinal Microbiome,Intestinal Microbiota,Intestinal Microflora,Bacteria, Enteric,Flora, Gastrointestinal,Flora, Gut,Flora, Intestinal,Gastric Microbiomes,Gastrointestinal Microbial Communities,Gastrointestinal Microbiomes,Gastrointestinal Microbiotas,Gut Microbiomes,Gut Microbiotas,Intestinal Microbiomes,Intestinal Microbiotas,Microbial Community, Gastrointestinal,Microbiome, Gastric,Microbiome, Gastrointestinal,Microbiome, Gut,Microbiome, Intestinal,Microbiota, Gastrointestinal,Microbiota, Gut,Microbiota, Intestinal,Microflora, Gastrointestinal,Microflora, Gut,Microflora, Intestinal
D000273 Adipose Tissue Specialized connective tissue composed of fat cells (ADIPOCYTES). It is the site of stored FATS, usually in the form of TRIGLYCERIDES. In mammals, there are two types of adipose tissue, the WHITE FAT and the BROWN FAT. Their relative distributions vary in different species with most adipose tissue being white. Fatty Tissue,Body Fat,Fat Pad,Fat Pads,Pad, Fat,Pads, Fat,Tissue, Adipose,Tissue, Fatty
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012336 RNA, Ribosomal, 16S Constituent of 30S subunit prokaryotic ribosomes containing 1600 nucleotides and 21 proteins. 16S rRNA is involved in initiation of polypeptide synthesis. 16S Ribosomal RNA,16S rRNA,RNA, 16S Ribosomal,Ribosomal RNA, 16S,rRNA, 16S
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus
D024821 Metabolic Syndrome A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components of metabolic syndrome include ABDOMINAL OBESITY; atherogenic DYSLIPIDEMIA; HYPERTENSION; HYPERGLYCEMIA; INSULIN RESISTANCE; a proinflammatory state; and a prothrombotic (THROMBOSIS) state. Cardiometabolic Syndrome,Insulin Resistance Syndrome X,Metabolic Syndrome X,Reaven Syndrome X,Dysmetabolic Syndrome X,Metabolic Cardiovascular Syndrome,Metabolic X Syndrome,Syndrome X, Insulin Resistance,Syndrome X, Metabolic,Cardiometabolic Syndromes,Cardiovascular Syndrome, Metabolic,Cardiovascular Syndromes, Metabolic,Metabolic Syndromes,Syndrome X, Dysmetabolic,Syndrome X, Reaven,Syndrome, Cardiometabolic,Syndrome, Metabolic,Syndrome, Metabolic Cardiovascular,Syndrome, Metabolic X,Syndromes, Cardiometabolic,Syndromes, Metabolic,X Syndrome, Metabolic

Related Publications

N K Newman, and Y Zhang, and J Padiadpu, and C L Miranda, and A A Magana, and C P Wong, and K A Hioki, and J W Pederson, and Z Li, and M Gurung, and A M Bruce, and K Brown, and G Bobe, and T J Sharpton, and N Shulzhenko, and C S Maier, and J F Stevens, and A F Gombart, and A Morgun
January 2010, Molecular and cellular endocrinology,
N K Newman, and Y Zhang, and J Padiadpu, and C L Miranda, and A A Magana, and C P Wong, and K A Hioki, and J W Pederson, and Z Li, and M Gurung, and A M Bruce, and K Brown, and G Bobe, and T J Sharpton, and N Shulzhenko, and C S Maier, and J F Stevens, and A F Gombart, and A Morgun
August 2009, Discovery medicine,
N K Newman, and Y Zhang, and J Padiadpu, and C L Miranda, and A A Magana, and C P Wong, and K A Hioki, and J W Pederson, and Z Li, and M Gurung, and A M Bruce, and K Brown, and G Bobe, and T J Sharpton, and N Shulzhenko, and C S Maier, and J F Stevens, and A F Gombart, and A Morgun
May 2022, Molecular nutrition & food research,
N K Newman, and Y Zhang, and J Padiadpu, and C L Miranda, and A A Magana, and C P Wong, and K A Hioki, and J W Pederson, and Z Li, and M Gurung, and A M Bruce, and K Brown, and G Bobe, and T J Sharpton, and N Shulzhenko, and C S Maier, and J F Stevens, and A F Gombart, and A Morgun
January 2016, Diabetes & metabolic syndrome,
N K Newman, and Y Zhang, and J Padiadpu, and C L Miranda, and A A Magana, and C P Wong, and K A Hioki, and J W Pederson, and Z Li, and M Gurung, and A M Bruce, and K Brown, and G Bobe, and T J Sharpton, and N Shulzhenko, and C S Maier, and J F Stevens, and A F Gombart, and A Morgun
February 2021, Obesity (Silver Spring, Md.),
N K Newman, and Y Zhang, and J Padiadpu, and C L Miranda, and A A Magana, and C P Wong, and K A Hioki, and J W Pederson, and Z Li, and M Gurung, and A M Bruce, and K Brown, and G Bobe, and T J Sharpton, and N Shulzhenko, and C S Maier, and J F Stevens, and A F Gombart, and A Morgun
December 2012, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir,
N K Newman, and Y Zhang, and J Padiadpu, and C L Miranda, and A A Magana, and C P Wong, and K A Hioki, and J W Pederson, and Z Li, and M Gurung, and A M Bruce, and K Brown, and G Bobe, and T J Sharpton, and N Shulzhenko, and C S Maier, and J F Stevens, and A F Gombart, and A Morgun
January 2016, Molecular therapy. Nucleic acids,
N K Newman, and Y Zhang, and J Padiadpu, and C L Miranda, and A A Magana, and C P Wong, and K A Hioki, and J W Pederson, and Z Li, and M Gurung, and A M Bruce, and K Brown, and G Bobe, and T J Sharpton, and N Shulzhenko, and C S Maier, and J F Stevens, and A F Gombart, and A Morgun
December 2023, Life sciences,
N K Newman, and Y Zhang, and J Padiadpu, and C L Miranda, and A A Magana, and C P Wong, and K A Hioki, and J W Pederson, and Z Li, and M Gurung, and A M Bruce, and K Brown, and G Bobe, and T J Sharpton, and N Shulzhenko, and C S Maier, and J F Stevens, and A F Gombart, and A Morgun
January 2021, Frontiers in microbiology,
N K Newman, and Y Zhang, and J Padiadpu, and C L Miranda, and A A Magana, and C P Wong, and K A Hioki, and J W Pederson, and Z Li, and M Gurung, and A M Bruce, and K Brown, and G Bobe, and T J Sharpton, and N Shulzhenko, and C S Maier, and J F Stevens, and A F Gombart, and A Morgun
October 2019, The Journal of clinical investigation,
Copied contents to your clipboard!